TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

~ Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technology ~ Collaboration focused on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery ~ Catalent to offer TFF Pharmaceuticals’ innovative Thin Film Freezing technology to complement its own capabilities of spray-drying for dry powder inhalation

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here